W2O symplur

News

W2O has chalked up its fifth acquisition in less than a year with a deal to buy healthcare social media analytics company Symplur.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.